News
SVRA
4.640
-1.69%
-0.080
Savara Stock Gets A Reality Check After Wider Quarterly Losses
Simply Wall St · 20h ago
Savara Announces New Employment Inducement Grant
Barchart · 1d ago
Savara Coverage Assumed by HC Wainwright & Co. at Buy
Dow Jones · 1d ago
Savara Price Target Announced at $10.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
SVRA's Quarterly Loss Matters Less Than What the FDA Decides Twelve Days Later
Barchart · 3d ago
Weekly Report: what happened at SVRA last week (1102-1106)?
Weekly Report · 4d ago
Savara (SVRA) Jumps 10% But Does Its 8.5x P B Still Look Pricey?
Simply Wall St · 6d ago
Big Pharma Has $1.2 Trillion to Spend and a Revenue Gap to Fill: Inside the F/m Emerald Life Sciences Innovation ETF (LFSC)
TipRanks · 11/02 12:00
Weekly Report: what happened at SVRA last week (1026-1030)?
Weekly Report · 11/02 09:19
Molgramostim Trial Update Might Change The Case For Investing In Savara (SVRA)
Simply Wall St · 10/29 09:42
Biotech Stocks Facing FDA Decision In November 2026
NASDAQ · 10/29 08:01
Savara (SVRA) Jumped, But What Is Behind The Fresh Attention?
Simply Wall St · 10/27 12:10
Strong Specialist Support for MOLBREEVI, Broad aPAP Opportunity Underpin Fein’s Unchanged $10 Price Target and Buy Rating
TipRanks · 10/26 15:45
Savara (SVRA) Gets a Buy from Piper Sandler
TipRanks · 10/26 11:45
Weekly Report: what happened at SVRA last week (1019-1023)?
Weekly Report · 10/26 09:19
Savara Presents Clinical Trial Post-Hoc Analysis Of IMPALA At CHEST 2026 Annual Meeting To Evaluate Effects Of Molgramostim In aPAP Patients
Benzinga · 10/21 17:13
Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
Barchart · 10/21 12:10
Weekly Report: what happened at SVRA last week (1012-1016)?
Weekly Report · 10/19 09:19
Molgramostim Data Preview Could Be A Big Test For Savara Stock (SVRA)
Simply Wall St · 10/13 08:26
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
Barchart · 10/12 15:05
More
Webull provides a variety of real-time SVRA stock news. You can receive the latest news about Savara Inc through multiple platforms. This information may help you make smarter investment decisions.
About SVRA
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company's lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.